MacroGenics (MGNX) said late Monday it will receive $24.5 million of regulatory milestone payments from Sanofi (SNY) following the US Food and Drug Administration's accelerated approval of Tzield to treat children aged eight to 17 with stage 3 type 1 diabetes.
The company remains eligible to receive up to $305 million in additional milestone payments, according to a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments